SP
SP4P.F Achieve Life Sciences Inc
- Market cap
- EUR 627M
- P/E
- -
- P/B
- 3.84x
- ROE
- -71.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is SP4P.F undervalued?
Graham numberThe Graham number of Achieve Life Sciences Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Achieve Life Sciences Inc fundamental analysis
No fundamental analysis for Achieve Life Sciences Inc yet.
Achieve Life Sciences Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Achieve Life Sciences Inc
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is he…
Full company profileAchieve Life Sciences Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Achieve Life Sciences Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 5.06M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -18.7M | -6.63M | -12.8M | -16.5M | -14.8M | -33.1M | -40.8M | -27.3M | -39.1M | -54.9M | -65.9M |
| EBITDA | - | -6.35M | -12.5M | -16.3M | -14.5M | -32.8M | -40.3M | -26.7M | -37.4M | -53.6M | -128M |
| Net Income | -20.1M | -10.6M | -12.7M | -16.4M | -14.7M | -33.2M | -42.4M | -29.8M | -39.8M | -54.6M | -129M |
| EPS | - | -177 | -38 | -11 | -2.41 | -3.51 | -2.37 | -1.41 | -1.15 | -1.03 | -1.18 |
| Balance Sheet | |||||||||||
| Total Assets | 27.5M | 9.89M | 19.1M | 21.1M | 40.3M | 47.5M | 30.0M | 19.4M | 38.6M | 41.8M | 206M |
| Total Liabilities | 8.50M | 2.01M | 3.28M | 3.03M | 3.01M | 19.5M | 21.7M | 20.8M | 17.7M | 20.3M | 25.7M |
| Shareholders' Equity | 19.0M | 7.88M | 15.8M | 18.1M | 37.3M | 28.0M | 8.30M | -1.45M | 20.9M | 21.5M | 181M |
| Cash & Short-term Investments | 15.2M | 5.28M | 9.52M | 16.7M | 35.9M | 43.0M | 24.8M | 15.5M | 12.7M | 20.9M | 59.7M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -202K | -9.11M | -10.6M | -15.2M | -13.5M | -29.4M | -37.5M | -24.5M | -29.8M | -49.5M | -34.8M |
| Capital Expenditure | 46.0K | 46.0K | 46.0K | 53.0K | 17.0K | 0.00 | 0.00 | 21.0K | 0.00 | 4.00K | 44.0K |
| Free Cash Flow | - | -9.11M | -10.7M | -15.3M | -13.5M | -29.4M | -37.5M | -24.5M | -29.8M | -49.5M | -35.0M |
| Ratios | |||||||||||
| ROE | -106.1% | -134.3% | -80.3% | -90.8% | -39.5% | -118.2% | -510.1% | - | -190.6% | -254.0% | -71.6% |
| ROA | -73.3% | -107.0% | -66.5% | -77.8% | -36.6% | -69.8% | -141.3% | -153.9% | -103.1% | -130.8% | -62.7% |
| Net Profit Margin | -397.6% | - | - | - | - | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Achieve Life Sciences Inc dividends
Achieve Life Sciences Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:20 on Aug 3, 2020.
Who owns Achieve Life Sciences Inc
- Insiders 0.85%
- Institutions 80.65%
- Public & others 18.50%
- Shares outstanding 110M
- Free float 79.9M
Achieve Life Sciences Inc company profile
- Company name
- Achieve Life Sciences Inc
- Ticker
- SP4P.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 28
- Fiscal year end
- December
- Address
- 22722 29th Dr. SE, Bothell, WA, United States, 98021
- Phone
- 604 210 2217
- Website
- achievelifesciences.com
About Achieve Life Sciences Inc
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.
Achieve Life Sciences Inc management
9- Mr. Erik AtkissonChief Legal Officer · born 1972
- Mr. Benjamin Halladay M.B.A.Chief Financial Officer · born 1986
- Mr. Jerry WanVP of Finance & Principal Accounting Officer · born 1982
- Ms. Kaitlyn TusonSenior Vice President of Marketing & Communications
- Dr. Mark L. Rubinstein M.D.Chief Medical Officer · born 1968
- Mr. Mark ZappiaSenior Vice President of Commercial
- Mr. Ronald DadinoSenior Vice President of Chemistry, Manufacturing & Controls and Supply Chain
- Ms. Gloria CosgroveSenior Vice President of Global Quality
- Ms. Nicole P. JonesVice President of Strategic Communications & Stakeholder Relations